Grifols SA (hemotherapy, diagnostics, and hospital IV drugs) is acquiring a 60% stake in privately held diagnostics company Progenika Biopharma SA for €37mm ($48mm), half of which was paid in cash and the rest in 885k nonvoting Class B Grifols shares (which are traded on the Spanish Mercado Continuo and Nasdaq). (Mar.)
Grifols and Progenika’s selling shareholders each have three-year call and put options regarding the acquisition of an additional 35% of...